Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation.
We have evaluated recovery of CD56 positive and other cell types following allogeneic stem cell transplantation and have found that the recovery of CD56 positive cells was faster than other lymphoid cells after allogeneic stem cell transplantation, while the recovery of CD4 positive cells was markedly delayed. Chimerism analysis showed that mixed chimerism was often observed in younger (<30 years old) patients. Mixed chimerism in older (> or =30 years old) patients was associated with rejection and relapse, while this was not found in younger patients. Among the chimerism of various cell populations, donor-derived CD56-positive cells are important in early engraftment when determined in allogeneic nonmyeloablative stem cell transplantation (allo-NST), regardless of the proportion of donor-derived CD3-positive cells. Complementarity-determining region three (CDR3) size spectratyping in T-cell receptor (TCR) chain subfamilies (Vbeta) showed that high level of diversity in TCR Vbeta repertoire is important for a late rejection and skewed TCR Vbeta repertoire is correlated with the occurrence of graft-versus-host disease (GVHD) especially chronic GVHD. Expression of inhibitory natural killer (NK) cell receptors such as CD158b and CD94/NKG2A on peripheral CD3-negative and -positive cells were increased in parallel with GVHD. Interestingly, these cells appeared to control GVHD, while preserving graft-versus-leukemia (GVL) effect. Analysis of cytokine gene expression in peripheral blood mononuclear cells showed that type 1 helper T cells (Th1)-derived cytokines increased in severe GVHD, while Th2-derived cytokines such as IL-4, IL-10 and IL-13 increased in mild GVHD. These results indicate that Th2 cells suppress GVHD, although Th1 cells augment GVHD. Taken together, evaluation of immune reconstitution and tolerance in patients receiving allogeneic stem cell transplantation from the various viewpoints is essential and useful to obtain better clinical outcome.
Imamura
Masahiro
M
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. mimamura@med.hokudai.ac.jp
Tsutsumi
Yutaka
Y
Miura
Yoko
Y
Toubai
Tomomi
T
Tanaka
Junji
J
D000328:Adult; D000367:Age Factors; D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000473:pathology*; D019002:CD56 Antigen / Q000032:analysis*; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000276:immunology / Q000473:pathology; D020544:Graft vs Leukemia Effect; D006410:Hematopoiesis; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D007135:Immunoglobulin Variable Region / Q000235:genetics; D007938:Leukemia / Q000628:therapy; D016131:Lymphocyte Subsets / Q000166:cytology* / Q000276:immunology; D051379:Mice; D018895:Microsatellite Repeats; D008875:Middle Aged; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D011971:Receptors, Immunologic / Q000032:analysis; D018183:Transplantation Chimera; D014184:Transplantation, Homologous / Q000473:pathology*
D015703:Antigens, CD; D019002:CD56 Antigen; D007135:Immunoglobulin Variable Region; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic